Cue Biopharma (CUE)
Market Price (5/11/2026): $34.52 | Market Cap: $124.4 MilSector: Health Care | Industry: Biotechnology
Cue Biopharma (CUE)
Market Price (5/11/2026): $34.52Market Cap: $124.4 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 196% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. | Trading close to highsDist 52W High is -2.0% Weak multi-year price returns2Y Excs Rtn is -90%, 3Y Excs Rtn is -155% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -27 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -97% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 17% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -79%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -80% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -25% High stock price volatilityVol 12M is 189% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 209% Key risksCUE key risks include [1] substantial doubt about its ability to continue as a going concern due to a limited cash runway and recurring losses, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 196% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. |
| Trading close to highsDist 52W High is -2.0% |
| Weak multi-year price returns2Y Excs Rtn is -90%, 3Y Excs Rtn is -155% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -27 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -97% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 17% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -79%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -80% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -25% |
| High stock price volatilityVol 12M is 189% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 209% |
| Key risksCUE key risks include [1] substantial doubt about its ability to continue as a going concern due to a limited cash runway and recurring losses, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Achievement of a $7.5 million preclinical milestone payment from Boehringer Ingelheim.
On April 8, 2026, Cue Biopharma announced it would receive a $7.5 million preclinical milestone payment from its collaboration and license agreement with Boehringer Ingelheim, expected in May 2026, for the advancement of a compound for lead optimization under their CUE-501 program. This news led to a significant stock increase, with shares rising 77% on April 10, 2026.
2. Exclusive licensing of Ascendant-221 and associated $30 million PIPE financing.
On April 30, 2026, Cue Biopharma entered into an exclusive license agreement with Ascendant Health Sciences Ltd. for Ascendant-221, a Phase 2 clinical-stage anti-IgE monoclonal antibody, involving a $15 million upfront license fee and potential milestone payments up to $676.5 million. Concurrently, the company announced a $30 million PIPE (Private Investment in Public Equity) financing to support its clinical pipeline, including the acquisition and development of Ascendant-221, leading to a substantial jump in stock price.
Show more
Stock Movement Drivers
Fundamental Drivers
The 248.5% change in CUE stock from 1/31/2026 to 5/10/2026 was primarily driven by a 286.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.04 | 35.00 | 248.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 27 | 286.8% |
| P/S Multiple | 4.8 | 4.6 | -3.5% |
| Shares Outstanding (Mil) | 3 | 4 | -6.7% |
| Cumulative Contribution | 248.5% |
Market Drivers
1/31/2026 to 5/10/2026| Return | Correlation | |
|---|---|---|
| CUE | 248.5% | |
| Market (SPY) | 3.6% | 20.8% |
| Sector (XLV) | -6.9% | -3.8% |
Fundamental Drivers
The 52.0% change in CUE stock from 10/31/2025 to 5/10/2026 was primarily driven by a 231.4% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.03 | 35.00 | 52.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 8 | 27 | 231.4% |
| P/S Multiple | 8.8 | 4.6 | -48.1% |
| Shares Outstanding (Mil) | 3 | 4 | -11.7% |
| Cumulative Contribution | 52.0% |
Market Drivers
10/31/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| CUE | 52.0% | |
| Market (SPY) | 5.5% | 18.3% |
| Sector (XLV) | 0.3% | 0.1% |
Fundamental Drivers
The 54.5% change in CUE stock from 4/30/2025 to 5/10/2026 was primarily driven by a 195.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 22.65 | 35.00 | 54.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 27 | 195.7% |
| P/S Multiple | 6.1 | 4.6 | -24.1% |
| Shares Outstanding (Mil) | 2 | 4 | -31.2% |
| Cumulative Contribution | 54.5% |
Market Drivers
4/30/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| CUE | 54.5% | |
| Market (SPY) | 30.4% | 17.2% |
| Sector (XLV) | 4.0% | 5.2% |
Fundamental Drivers
The -73.1% change in CUE stock from 4/30/2023 to 5/10/2026 was primarily driven by a -96.6% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 129.90 | 35.00 | -73.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 27 | 2106.1% |
| P/S Multiple | 136.3 | 4.6 | -96.6% |
| Shares Outstanding (Mil) | 1 | 4 | -63.8% |
| Cumulative Contribution | -73.1% |
Market Drivers
4/30/2023 to 5/10/2026| Return | Correlation | |
|---|---|---|
| CUE | -73.1% | |
| Market (SPY) | 78.7% | 16.9% |
| Sector (XLV) | 13.0% | 10.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CUE Return | -10% | -75% | -7% | -59% | -72% | 290% | -90% |
| Peers Return | 7% | -2% | -1% | 80% | -6% | -2% | 71% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| CUE Win Rate | 50% | 33% | 50% | 25% | 42% | 60% | |
| Peers Win Rate | 51% | 45% | 48% | 52% | 50% | 48% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| CUE Max Drawdown | -20% | -80% | -40% | -83% | -78% | -42% | |
| Peers Max Drawdown | -17% | -28% | -25% | -20% | -36% | -12% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: XNCR, JANX, AMGN, REGN, GILD. See CUE Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)
How Low Can It Go
| Event | CUE | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -33.0% | -7.8% |
| % Gain to Breakeven | 49.2% | 8.5% |
| Time to Breakeven | 6 days | 18 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -29.1% | -6.7% |
| % Gain to Breakeven | 41.1% | 7.1% |
| Time to Breakeven | 18 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -52.2% | -33.7% |
| % Gain to Breakeven | 109.3% | 50.9% |
| Time to Breakeven | 33 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -46.6% | -19.2% |
| % Gain to Breakeven | 87.1% | 23.7% |
| Time to Breakeven | 82 days | 105 days |
In The Past
Cue Biopharma's stock fell -33.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 49.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CUE | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -33.0% | -7.8% |
| % Gain to Breakeven | 49.2% | 8.5% |
| Time to Breakeven | 6 days | 18 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -29.1% | -6.7% |
| % Gain to Breakeven | 41.1% | 7.1% |
| Time to Breakeven | 18 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -52.2% | -33.7% |
| % Gain to Breakeven | 109.3% | 50.9% |
| Time to Breakeven | 33 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -46.6% | -19.2% |
| % Gain to Breakeven | 87.1% | 23.7% |
| Time to Breakeven | 82 days | 105 days |
In The Past
Cue Biopharma's stock fell -33.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 49.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Cue Biopharma (CUE)
AI Analysis | Feedback
Imagine a "precision immunotherapy lab" focused on designing smart biologic drugs to specifically activate your immune system's T-cells to fight diseases. Cue Biopharma is building this next generation of targeted immune therapies, much like a specialized, early-stage Genentech or Amgen.
Think of Cue Biopharma as a company developing highly specific "on-switches" for your immune system. They're creating novel biologic drugs to precisely instruct T-cells to attack cancers and other serious illnesses, similar to how a more targeted Merck might evolve its immunotherapy approach beyond broad checkpoint inhibitors.
AI Analysis | Feedback
```html- CUE-101: A fusion protein biologic in Phase 1b clinical trial designed to activate T cells for human papilloma virus-driven cancers.
- CUE-102: A fusion protein biologic designed to target and activate antigen-specific T cells to fight cancers.
- CUE-103: A CUE-100 series Immuno-STAT targeting the KRAS G12V mutation for various cancers including colorectal, lung, and pancreatic.
- CUE-200: A drug framework that focuses on cell surface receptors to address T cell exhaustion associated with chronic infections.
- CUE-300 framework: A drug framework developed to target various autoimmune diseases.
- CUE-400 framework: A drug framework developed to target various autoimmune diseases.
AI Analysis | Feedback
Cue Biopharma (CUE) is a clinical-stage biopharmaceutical company focused on the research and development of biologic drugs. As such, it does not currently sell drugs directly to individuals or through traditional distribution channels. Its revenue primarily stems from collaboration agreements and partnerships with other companies and research institutions.
Based on the provided information, Cue Biopharma's major customers and partners include:
- Merck Sharp & Dohme Corp. (Symbol: MRK)
- LG Chem Life Sciences (part of LG Chem, Symbol: 051910.KS)
- Albert Einstein College of Medicine
AI Analysis | Feedback
nullAI Analysis | Feedback
Usman “Oz” Azam, M.D. President and Chief Executive Officer
Dr. Azam brings over 25 years of leadership experience in drug discovery, development, and operations to Cue Biopharma. He previously served as Chief Executive Officer of Inspirna, Inc., a privately held clinical-stage biopharmaceutical company, and Empyrean Neuroscience, a genetic engineering company. He was also the President and CEO of Tmunity Therapeutics, which developed genetically engineered CAR-T cell therapies. Prior to these roles, Dr. Azam was the Global Head of the Cell and Gene Therapies unit at Novartis, where he played a key role in the launch of the first-ever FDA-approved CAR-T cell therapy. His career also includes leadership positions at Pfizer Pharmaceuticals, Aspreva Pharmaceuticals, Johnson & Johnson, and GlaxoSmithKline (GSK).
Lucinda Warren Chief Financial Officer and Business Officer
Ms. Warren has over 30 years of global experience in the pharmaceutical and biotechnology sectors. Before joining Cue Biopharma, she was the Vice President of Business Development for Neuroscience and Japan Regionally at Johnson & Johnson from 2014 to 2024. In this role, she was responsible for end-to-end business development, including licensing, mergers and acquisitions, and alliance management. Ms. Warren has also held leadership positions at Janssen Cilag Australia and Janssen Biologics.
Anish Suri, Ph.D. Chief Scientific Officer
Dr. Suri serves as the President and Chief Scientific Officer at Cue Biopharma Inc. He previously held the position of Senior Vice President and Chief Scientific Officer at the company and served as an Assistant Professor of Pathology & Immunology at Washington University.
Colin Sandercock, M.S.E., J.D. Senior Vice President and General Counsel
Mr. Sandercock has over 30 years of experience providing legal counsel to life sciences companies on a wide range of matters, including domestic and international patent litigation, compliance, procurement, and licensing. Before joining Cue Biopharma, he was a Partner at Perkins Coie, a position he held since 2009.
Daniel Baker, M.D. Interim Chief Development Officer
Dr. Baker is the Interim Chief Development Officer at Cue Biopharma.
AI Analysis | Feedback
Here are the key risks to Cue Biopharma's business:
- Financial Health and Going Concern: Cue Biopharma is a clinical-stage biopharmaceutical company with a history of significant operating losses and negative cash flows, and it has not yet generated commercial revenue from product sales. The company's recurring losses raise substantial doubt about its ability to continue as a going concern, as indicated by its Altman Z-Score which places it in a distress zone. Its survival is heavily dependent on its ability to secure consistent, non-dilutive funding, often through strategic partnerships or future capital raises, to cover its significant research and development expenses and sustain operations.
- Clinical Trial and Regulatory Risk: The success of Cue Biopharma is fundamentally reliant on the successful development, clinical testing, and regulatory approval of its drug candidates, such as CUE-101 and CUE-401. As a company with only a few drug candidates currently in clinical trials, any setbacks, delays, or failures in these trials, or an inability to obtain necessary regulatory approvals from agencies like the FDA, would have a material adverse impact on its business, financial condition, and future growth prospects.
- Dependence on Collaborations and External Funding: Cue Biopharma's revenue stream is primarily derived from collaboration agreements with third parties, rather than product sales. The continuation and success of these partnerships are critical, as the company depends on upfront payments and milestone recognition from these agreements to fund its operations and pipeline development. The termination or reduction of any key collaboration agreements could significantly impact its financial stability and ability to advance its drug candidates.
AI Analysis | Feedback
null
AI Analysis | Feedback
Cue Biopharma's main products target several significant addressable markets globally:
- CUE-101 (targeting Human Papillomavirus (HPV)-driven cancers, specifically HPV16-positive Head and Neck Squamous Cell Carcinoma (HNSCC)): The global HPV associated disorders treatment market was valued at USD 19.6 billion in 2023 and is projected to grow to USD 30.1 billion by 2032. More specifically, the HPV16-positive HNSCC market was approximately USD 810 million in 2024 across the 7MM (United States, EU4: Germany, France, Italy, Spain, United Kingdom, and Japan). Additionally, the global cervical cancer treatment market is projected to grow from an estimated US$8.6 billion in 2024 to US$11.8 billion by 2030.
- CUE-103 (targeting KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer):
- Colorectal Cancer: The global colorectal cancer market size was evaluated at USD 13 billion in 2023 and is slated to reach USD 20 billion by the end of 2032. The global metastatic colorectal cancer market is projected to reach USD 19.06 billion by 2035, from USD 6.78 billion in 2024.
- Lung Cancer: The global lung cancer market is estimated to be valued at USD 31.72 billion in 2026 and is expected to reach USD 73.70 billion by 2033.
- Pancreatic Cancer: The global pancreatic cancer treatment market size was estimated at USD 2.92 billion in 2024 and is projected to reach USD 5.84 billion by 2030. Another estimate indicates the global pancreatic cancer industry will increase from USD 2.65 billion in 2024 to USD 9.57 billion by 2034.
- CUE-200 (focusing on T cell exhaustion associated with chronic infections): The global infectious disease therapeutics market size was estimated at USD 243,409.1 million in 2024 and is projected to reach USD 283,908.2 million by 2030.
- CUE-300 and CUE-400 (targeting various autoimmune diseases): The global autoimmune disease therapeutics market size was worth around USD 123.96 billion in 2024 and is predicted to grow to around USD 249.71 billion by 2034.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Cue Biopharma (CUE) over the next 2-3 years:
- Milestone and Upfront Payments from Strategic Collaborations: Cue Biopharma's revenue primarily stems from collaboration agreements as it is a clinical-stage biopharmaceutical company without commercial product sales. Significant drivers include upfront payments and potential milestone payments from existing and future partnerships. For instance, the company has a collaboration and license agreement with Boehringer Ingelheim for CUE-501, which included an upfront payment of $12 million in April 2025 and potential milestone payments totaling approximately $345 million. Another strategic collaboration with ImmunoScape, announced in November 2025, provides for $15 million in upfront payments ($10 million in Q4 2025 and $5 million in November 2026) and a 40% equity stake in ImmunoScape. The successful execution of these agreements and the initiation of new collaborations for its Immuno-STAT platform, especially in the autoimmune space, are critical for revenue growth.
- Advancement of Clinical Pipeline Candidates: Progress in the clinical development of its lead drug candidates is a key driver for future revenue. CUE-101, a fusion protein biologic in Phase 1b clinical trials for HPV-driven cancers, has shown promising clinical data, including a confirmed 50% Overall Response Rate (ORR) in combination with pembrolizumab and a median Overall Survival (mOS) of 32.7 months. Further advancement of CUE-101 towards later-stage trials and potential regulatory approval, as well as the progression of other oncology candidates like CUE-102 and CUE-103, could lead to increased partnership interest or eventual commercialization revenue.
- Development of Autoimmune Disease Programs: Cue Biopharma has strategically pivoted to prioritize its autoimmune disease programs, with CUE-401 being a lead candidate aiming to address high unmet medical needs. Advancing CUE-401 towards clinical trials is a significant focus, and promising preclinical data for CUE-401 was presented in March 2026. The company's CUE-500 series, including CUE-501, also targets autoimmune and inflammatory diseases and is part of the Boehringer Ingelheim collaboration. Successful development and potential partnering of these autoimmune assets represent a substantial long-term revenue opportunity.
- Potential Royalty Streams from Commercialized Products: While not expected in the immediate 2-3 years given the clinical-stage nature of its pipeline, the long-term revenue growth could be driven by royalty payments on net sales if any of its partnered drug candidates, such as CUE-501 or products developed through the ImmunoScape collaboration, successfully reach commercialization.
AI Analysis | Feedback
Share Issuance
Cue Biopharma priced an underwritten public offering in December 2025 to raise approximately $10 million in gross proceeds through the sale of common stock and accompanying warrants. In September 2024, the company priced another underwritten public offering, generating approximately $12.0 million in gross proceeds from common stock and warrants. An underwritten public offering in April 2025 aimed to raise approximately $20 million in gross proceeds, also through common stock and warrants. Additionally, in November 2022, Cue Biopharma secured $30 million from a private investment in public equity (PIPE) financing, involving the sale of common stock and pre-funded warrants with accompanying warrants.Inbound Investments
In November 2025, Cue Biopharma entered into a strategic collaboration and license agreement with ImmunoScape, which includes an upfront payment of $15 million ($10 million in Q4 2025 and $5 million in November 2026) and a 40% equity stake in ImmunoScape. Earlier in April 2025, the company announced a strategic research collaboration and license agreement with Boehringer Ingelheim for CUE-501, which provided an upfront payment of $12 million and ongoing research support payments. A $30 million private investment in public equity (PIPE) financing from accredited investors, including a new life sciences-focused investment fund, was completed in November 2022.Outbound Investments
As part of its strategic collaboration and license agreement with ImmunoScape in November 2025, Cue Biopharma is entitled to a 40% equity stake in ImmunoScape.Capital Expenditures
Cue Biopharma invested $66K in capital expenditures during fiscal year 2024, which was utilized to fund long-term assets and infrastructure.Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CUE.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 83.17 |
| Mkt Cap | 37.7 |
| Rev LTM | 7,508 |
| Op Inc LTM | 1,908 |
| FCF LTM | 1,885 |
| FCF 3Y Avg | 1,764 |
| CFO LTM | 2,496 |
| CFO 3Y Avg | 2,268 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.5% |
| Rev Chg 3Y Avg | 10.5% |
| Rev Chg Q | 5.8% |
| QoQ Delta Rev Chg LTM | 2.6% |
| Op Inc Chg LTM | 3.7% |
| Op Inc Chg 3Y Avg | -3.1% |
| Op Mgn LTM | -35.4% |
| Op Mgn 3Y Avg | -58.2% |
| QoQ Delta Op Mgn LTM | 2.0% |
| CFO/Rev LTM | -25.0% |
| CFO/Rev 3Y Avg | -47.9% |
| FCF/Rev LTM | -28.3% |
| FCF/Rev 3Y Avg | -53.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 37.7 |
| P/S | 5.2 |
| P/Op Inc | 4.6 |
| P/EBIT | 4.5 |
| P/E | 6.0 |
| P/CFO | 4.8 |
| Total Yield | -3.2% |
| Dividend Yield | 0.3% |
| FCF Yield 3Y Avg | -0.3% |
| D/E | 0.1 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -4.8% |
| 3M Rtn | -0.2% |
| 6M Rtn | 7.0% |
| 12M Rtn | 37.7% |
| 3Y Rtn | 2.7% |
| 1M Excs Rtn | -13.0% |
| 3M Excs Rtn | -6.9% |
| 6M Excs Rtn | -2.1% |
| 12M Excs Rtn | 0.8% |
| 3Y Excs Rtn | -88.8% |
Price Behavior
| Market Price | $35.00 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 01/02/2018 | |
| Distance from 52W High | -2.0% | |
| 50 Days | 200 Days | |
| DMA Price | $13.74 | $16.82 |
| DMA Trend | down | up |
| Distance from DMA | 154.7% | 108.0% |
| 3M | 1YR | |
| Volatility | 334.3% | 190.1% |
| Downside Capture | -2.71 | -0.02 |
| Upside Capture | 177.03 | 45.25 |
| Correlation (SPY) | 14.8% | 13.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.88 | 3.95 | 3.50 | 2.75 | 2.11 | 1.39 |
| Up Beta | 8.00 | 8.30 | 7.16 | 6.10 | 2.70 | 1.89 |
| Down Beta | 158.39 | 12.95 | 8.39 | 6.18 | 5.25 | 2.27 |
| Up Capture | 315% | 250% | 186% | 12% | 34% | 4% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 11 | 22 | 32 | 57 | 116 | 324 |
| Down Capture | -6209% | -329% | -36% | 59% | 104% | 103% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 11 | 21 | 32 | 68 | 134 | 414 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CUE | |
|---|---|---|---|---|
| CUE | 52.1% | 189.0% | 0.93 | - |
| Sector ETF (XLV) | 7.9% | 15.4% | 0.30 | 4.9% |
| Equity (SPY) | 29.0% | 12.5% | 1.83 | 17.4% |
| Gold (GLD) | 39.8% | 27.0% | 1.22 | 4.8% |
| Commodities (DBC) | 50.6% | 18.0% | 2.21 | -4.7% |
| Real Estate (VNQ) | 13.0% | 13.5% | 0.66 | 10.6% |
| Bitcoin (BTCUSD) | -17.4% | 42.1% | -0.34 | 13.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CUE | |
|---|---|---|---|---|
| CUE | -37.5% | 121.0% | 0.10 | - |
| Sector ETF (XLV) | 4.9% | 14.6% | 0.16 | 13.3% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 22.2% |
| Gold (GLD) | 20.9% | 17.9% | 0.95 | 5.3% |
| Commodities (DBC) | 13.8% | 19.1% | 0.59 | 5.2% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 15.2% |
| Bitcoin (BTCUSD) | 7.0% | 56.0% | 0.34 | 12.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CUE | |
|---|---|---|---|---|
| CUE | -20.5% | 104.6% | 0.17 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 18.3% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 25.0% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | 6.6% |
| Commodities (DBC) | 9.3% | 17.8% | 0.44 | 9.5% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 16.7% |
| Bitcoin (BTCUSD) | 67.8% | 66.9% | 1.07 | 12.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/16/2026 | -12.8% | -14.5% | 132.5% |
| 11/12/2025 | -7.2% | -13.1% | -30.7% |
| 8/12/2025 | 2.6% | 3.3% | -3.1% |
| 3/31/2025 | -17.7% | -31.3% | -17.1% |
| 5/9/2024 | -9.1% | -9.1% | -24.8% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 1 |
| # Negative | 4 | 4 | 4 |
| Median Positive | 2.6% | 3.3% | 132.5% |
| Median Negative | -11.0% | -13.8% | -21.0% |
| Max Positive | 2.6% | 3.3% | 132.5% |
| Max Negative | -17.7% | -31.3% | -30.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/16/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/21/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/16/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Collaboration Revenue | 5.00 Mil | 0 | Affirmed | Guidance: 5.00 Mil for 2026 | |||
Prior: Q3 2025 Earnings Reported 11/12/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2025 Collaboration Revenue | 10.00 Mil | Higher New | |||||
| 2026 Collaboration Revenue | 5.00 Mil | Higher New | |||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sarraf, Pasha | Direct | Buy | 1022026 | 0.31 | 323,857 | 99,747 | 99,747 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.